- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Attovia Therapeutics, Inc. Common Stock(ATTO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATTO
11/13/2026: ATTO (1-star) is currently NOT-A-BUY. Pass it for now.
Attovia Therapeutics is a clinical-stage biotechnology company that develops precision biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY discovery platform. The company's main strengths include a well-funded balance sheet following its public offering and positive early clinical data for its lead pruritus candidate, ATTO-1310. Its primary growth story centers on advancing its pipeline of tunable biparatopic and multiparatopic biologics into mid-stage trials. Key risks involve high cash burn, clinical trial execution uncertainties, and intense competition from entrenched pharmaceutical blockbusters. The stock suits growth-oriented investors willing to accept high volatility in exchange for potential clinical breakthroughs, with a close operational focus on upcoming trial readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth exposure to novel clinical-stage biotherapeutic pipelines targeting large immunological markets. |
| Momentum investor | Strong fit while signal remains positive | Clinical trial readouts and regulatory catalysts can generate significant short-term price momentum. |
| Value investor | Weak fit | The stock lacks earnings, positive cash flow, and traditional valuation metrics typical of value investments. |
| Dividend investor | Weak fit | As a clinical-stage biotechnology firm, Attovia does not pay dividends. |
| Low-risk investor | Weak fit | Clinical development risks and high stock volatility present substantial risks unsuited for conservative profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price swings around clinical trial data releases. |
| Valuation risk | High | Valuations rely heavily on long-term clinical and commercial projections rather than current revenues or earnings. |
| Competition risk (large pharmaceutical immunology blockbusters) | Medium / high | Well-established drugs from major competitors command significant existing market share. |
| Business quality | Medium | The company possesses an innovative proprietary discovery platform but lacks a commercial product portfolio. |
| Dividend income | Low / none | All capital is retained to fund research and clinical trials rather than distributed to shareholders. |
| Execution risk | High | Success depends entirely on the ability to advance clinical trials efficiently and secure regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 691.63M USD | Price to earnings Ratio - | 1Y Target Price 43.2 |
Price to earnings Ratio - | 1Y Target Price 43.2 | ||
Volume (30-day avg) 338.2K shares | Beta - | 52 Weeks Range 12.94 - 28.00 | Updated Date 11/15/2026 |
52 Weeks Range 12.94 - 28.00 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.53 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Insufficient Data
The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
The stock price exhibits a Insufficient Data stability pattern.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing Agreements | Early-stage research collaborations and licensing fees associated with the ATTOBODY platform. | The company currently generates negligible revenue and operates at a net loss while funding drug development. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 299.53M | Price to Sales(TTM) 384.24 |
Enterprise Value 299.53M | Price to Sales(TTM) 384.24 | ||
Enterprise Value to Revenue 208.01 | Enterprise Value to EBITDA - | Shares Outstanding 45.71M | Shares Floating 26.26M |
Shares Outstanding 45.71M | Shares Floating 26.26M | ||
Percent Insiders 11.23 | Percent Institutions 37.72 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

